9 Biotech Penny Stocks to Buy
6. Luna Innovations (LUNA)Market Cap: $24.14 million
Luna Innovations (LUNA) is engaged in research, development and commercializing of technologies in two primary areas of focus: test and measurement, sensing, and instrumentation products and health care products. Luna shares have gained an impressive 196.8% since the end of Aug. 2009 despite the dip share prices have taken this summer. Don't count out the long-term earning potential for this Roanoke, Va.-based small-cap.
7. Neuralstem (CUR)Market Cap: $90.72 million
Neuralstem (CUR) is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The future could be bright as the company continues to work into their clinical trials to treat Lou Gehrig's disease; shares of this Rockland, Md.-based Neuralstem have gone up in value 80% since this time last year.
8. AVI BioPharma (AVII)Market Cap: $246.311 million
AVI BioPharma (AVII) is a biopharmaceutical company specializing in the discovery and development of ribonucleic acid (RNA) based drugs targeting a range of diseases. AVII shares have been on an impressive climb this summer and shareholders have already enjoyed 54% gains since June. The Washington-based company has also beat earnings estimates during two of the past three quarters and is getting the attention of savvy investors looking to add some stability to their portfolio.
9. DUSA Pharmaceuticals (DUSA)Market Cap: $55.44 million DUSA Pharmaceuticals (DUSA) is a vertically integrated dermatology company that is developing and marketing Levulan photodynamic therapy and other products for common skin conditions. With 99% increases in DUSA share value from one year ago, investors who haven't heard of this small-cap stock will likely be taking notice of the high-value and low financial commitment involved in DUSA stock. As of this writing, Louis Navellier did not own a position in any of the stocks named here.
More From Investor Place
|Top 6 Stocks for August|
|9 of the Worst Blue Chips Out There|
|Three Good Dividend Stocks to Buy on Bad Days|
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV